Home/ Stocks/ MTVA

MetaVia Inc. Common Stock

MTVA XNAS

$1.09 -0.21 (-15.79%) ▼ 15-min delayed

Open

$1.28

High

$1.33

Low

$1.00

Volume

484.1K

Market Cap

$5.63M

About MetaVia Inc. Common Stock

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 8 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$510.0K	$-12,973,000	$-7.35
FY 2025	$510.0K	$-12,973,000	$-7.35
Q3 2025	$151.0K	$-3,377,000	$-0.14
Q2 2025	$146.0K	$-3,995,000	$-0.26

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for MTVA yet. Check out our latest market news or earnings calendar.

Get MTVA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on MetaVia Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.